GLUCOCEREBROSIDASE GENE THERAPY FOR PARKINSON'S DISEASE

(19)

(11)

EP 3 292 206 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	09.02.2022 Bulletin 2022/06

(45)	Mention of the grant of the patent:
	22.12.2021 Bulletin 2021/51

(21)	Application number: 16724546.3

(22)	Date of filing: 06.05.2016

(51)

International Patent Classification (IPC):

C12N 15/864^(2006.01)
A61K 48/00^(2006.01)
A61P 25/16^(2006.01)

A61K 38/47^(2006.01)
A61K 35/76^(2015.01)
C12N 9/24^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 38/47; A61K 35/76; C12Y 302/01045; A01K 2227/105; A01K 2267/0356; C12N 2750/14143; A61P 25/16; A61K 48/0058; C12N 9/2405; C12N 2750/14171

(86)	International application number:
	PCT/US2016/031223

(87)	International publication number:
	WO 2016/179497 (10.11.2016 Gazette 2016/45)

(54)	GLUCOCEREBROSIDASE GENE THERAPY FOR PARKINSON'S DISEASE GLUCOCEREBROSIDASE GENTHERAPIE VON MORBUS PARKINSON GLUCOCÉRÉBROSIDASE THERAPIE GENIQUE POUR LA MALADIE DE PARKINSON

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

07.05.2015 US 201562158244 P

(43)	Date of publication of application:
	14.03.2018 Bulletin 2018/11

(73)	Proprietors:
	Takeda Pharmaceutical Company Limited Osaka-shi, Osaka (JP) The McLean Hospital Corporation Belmont, MA 02478 (US)

(72)	Inventors:
	PARK, Yung Hee Lexington, MA 02421 (US) ISACSON, Ole Belmont, MA 02478 (US)

(74)	Representative: Carpmaels & Ransford LLP
	One Southampton Row London WC1B 5HA London WC1B 5HA (GB)

(56)

References cited: :

WO-A1-2014/071282
US-A1- 2011 038 851

WO-A1-2015/060722

S. P. SARDI ET AL: "CNS expression of glucocerebrosidase corrects -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 29, 5 July 2011 (2011-07-05) , pages 12101-12106, XP055298671, US ISSN: 0027-8424, DOI: 10.1073/pnas.1108197108
EMILY M. ROCHA ET AL: "Glucocerebrosidase gene therapy prevents [alpha]-synucleinopathy of midbrain dopamine neurons", NEUROBIOLOGY OF DISEASE., vol. 82, 1 October 2015 (2015-10-01), pages 495-503, XP055298642, GB ISSN: 0969-9961, DOI: 10.1016/j.nbd.2015.09.009

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).